Pfenex Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
11,914.00
10,644.00
9,583.00
60,194.00
28,780.00
14,857
Cost of Goods Sold (COGS) incl. D&A
7,416.00
8,227.00
5,712.00
6,514.00
6,562.00
6,651
Gross Income
4,498.00
2,417.00
3,871.00
53,680.00
22,218.00
8,206
SG&A Expense
11,195.00
12,134.00
31,709.00
48,557.00
48,193.00
58,157
EBIT
6,697.00
9,717.00
27,838.00
5,123.00
25,975.00
49,951
Non Operating Income/Expense
-
-
164.00
157.00
119.00
258
Interest Expense
36.00
77.00
90.00
8.00
-
-
Pretax Income
6,733.00
9,794.00
27,764.00
5,272.00
25,856.00
49,693
Income Tax
2,671.00
-
452.00
209.00
172.00
10,100
Consolidated Net Income
4,062.00
9,794.00
28,216.00
5,481.00
25,684.00
39,593
Net Income
4,062.00
9,794.00
28,216.00
5,481.00
25,684.00
39,593
Net Income After Extraordinaries
4,062.00
9,794.00
28,216.00
5,481.00
25,684.00
39,593
Net Income Available to Common
5,757.00
9,794.00
28,216.00
5,481.00
25,684.00
39,593
EPS (Basic)
0.28
1.04
1.26
0.23
1.09
1.40
Basic Shares Outstanding
20,377.00
9,441.00
22,376.00
23,389.00
23,503.00
28,340
EPS (Diluted)
0.28
1.04
1.26
0.23
1.09
1.40
Diluted Shares Outstanding
20,377.00
9,441.00
22,376.00
23,688.00
23,503.00
28,340
EBITDA
5,704.00
8,723.00
26,766.00
6,324.00
24,569.00
48,271
Preferred Dividends
1,695.00
-
-
-
-
-

About Pfenex

View Profile
Address
10790 Roselle Street
San Diego California 92121
United States
Employees -
Website http://www.pfenex.com
Updated 07/08/2019
Pfênex, Inc. is a clinical-stage biotechnology company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes biosimilars and vaccines. The company was founded on November 19, 2009 and is headquartered in San Diego, CA.